US EditionADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
- ADC Therapeutics SA will host a conference call and live webcast on August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates.
- ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma.
- ADC Therapeutics is developing a next-generation PSMA-targeting ADC utilizing a differentiated payload.
- ADC Therapeutics is headquartered in Lausanne, Switzerland, and focuses on innovation in ADC development through specialized capabilities.
Insights by Ground AI
Does this summary seem wrong?
34 Articles
34 Articles
LoudounTimes.com+33 Reposted by 33 other sources
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday,…
Coverage Details
Total News Sources34
Leaning Left3Leaning Right5Center9Last UpdatedBias Distribution53% Center
Bias Distribution
- 53% of the sources are Center
53% Center
L 18%
C 53%
R 29%
Factuality
To view factuality data please Upgrade to Premium
